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Plakophilin 2, a member of the arm-repeat protein family, is a dual
location protein that occurs both in the cytoplasmic plaques of
desmosomes as an architectural component and in an extractable
form in the nucleoplasm. Here we report the existence of two nuclear
particles containing plakophilin 2 and the largest subunit of RNA
polymerase (pol) III (RPC155), both of which colocalize and are coim-
munoselected with other pol III subunits and with the transcription
factor TFIIIB. We also show that plakophilin 2 is present in the pol III
holoenzyme, but not the core complex, and that it binds specifically
to RPC155 in vitro. We propose the existence of diverse nuclear
particles in which proteins known as plaque proteins of intercellular
junctions are complexed with specific nuclear proteins.
In recent years, several components of the plaques of intercel-lular junctions surprisingly have also been identified in cell
nuclei, suggesting their involvement in nuclear functions and
regulatory interactions between the cell periphery and the
nucleus. Such proteins include members of the arm-repeat
family, which are characterized by variable numbers of a 42-
amino acid motif (1). Among these, the plakophilins (PKPs) are
characteristic of desmosomes and also occur constitutively in the
nucleoplasm of a wide range of cells (2–11). These positively
charged proteins (isoelectric points ranging from 9.3 to 10.1)
represent the products of three genes, PKP1, PKP2, and PKP3,
and at least PKP1 and PKP2 occur in two splice variants a and
b (3–12). Both variants can also be detected in the nuclei of
various cells devoid of desmosomes and after cDNA transfection
have also been shown to accumulate in the nuclei (9).
The observation of plakophilins in the nucleus, however, has
been possible only with the use of appropriate immunocyto-
chemical protocols that minimize the extraction of soluble
nucleoplasmic proteins and particles (e.g., see refs. 6, 9, and
13–15). Moreover, in a wide range of different kinds of cells
lacking desmosomes including fibroblasts, lymphocytes, and
chicken erythrocytes, plakophilins have been detected exclu-
sively in the nucleus (6, 7, 10, 11). This finding suggests that
plakophilins are constitutive nuclear proteins that, in certain
pathways of cell differentiation, are recruited to a second specific
location in desmosomal plaques (6–9).
Plakophilins 2a (92.75 kDa) and 2b (97.41 kDa) are of special
importance, because they display the most widespread occurrence
in desmosomes of all simple and complex epithelia, in lower layers
of many stratified epithelia, in all carcinomas, in heart muscle, in
reticulum cells of lymph node follicles, and in early embryos (6–8).
Therefore, we have decided to characterize the plakophilin 2-con-
taining structures of nuclei. Here we show plakophilin 2 in com-
plexes with the largest subunit of RNA polymerase (pol) III and
other pol III polypeptides, and we describe nucleoplasmic particles
combining plakophilin 2 with pol III proteins.
Materials and Methods
Cell Cultures. The following human cell culture lines were used:
HaCaT keratinocytes (16), vulvar squamous carcinoma-derived
A-431, hepatocellular carcinoma PLC, mammary gland carci-
noma MCF-7, cervical adenocarcinoma HeLa, HEK (embryonic
kidney), acute myeloid leukemia KG1a, and promyelocytic
leukemia HL60 (all from the American Type Culture Collec-
tion). In addition, several cells and tissues of human and other
vertebrate origins were examined including chicken erythrocytes
and Xenopus laevis ovary (7). Several of these cell lines, notably
HaCaT cells, were also used for the isolation of nuclei according
to the method of Lee and Green (17)
Antibodies. Immunoselections were performed with guinea pig
antibodies specific for plakophilin 2 (6) and rabbit antisera
against one of the following components of human pol III:
hRPC155 (CSH499), hRPC39, hRPC82, hTFIIIB90, and
hTFIIIC63 (18–21). Guinea pig antibodies specific for RPC155
were generated by immunization with the synthetic carboxyl-
terminal peptide PKRPLIFDTNEFHIPLVT (residues 1374–
1391) coupled to keyhole limpet hemocyanin and affinity-
purified. Immunoblotting for plakophilin 2 was performed with
the monoclonal antibodies PP2–150, PP2–86 (6–8), or plako-
philin 2a (Becton Dickinson and Transduction Laboratories,
Lexington, KY).
Sucrose Gradient Centrifugation and Gel Filtration Chromatography.
For sucrose gradient centrifugation, cells grown on 10-cm plates
were lysed with either 0.6 ml of ice-cold 5:1 buffer [83 mM KCl, 17
mM NaCl, 10 mM Tris-HCl, pH 7.4, 5 mM EDTA, 3 mM DTT, 1
mM PMSF, and 13 Complete protease inhibitors (Roche Molec-
ular Biochemicals)] or physiological salt buffer (140 mM NaCl, 1.5
mM MgCl2, 15 mM Hepes, pH 7.4, and 13 Complete), both
containing 0.1% Triton X-100. Cells were scraped off with a rubber
policeman, resuspended by pipetting, and transferred to a 1.5-ml
tube. To analyze the influence of nucleases, extracts were incubated
with either 16 mgyml RNase A (Roche) or 416 mgyml DNase for
15 min on ice. Digestion with DNase was performed with cell
extracts in 2 mM MgCl2 instead of 5 mM EDTA. After centrifu-
gation at 15,000 3 g and 4°C for 10 min, the supernatant was
centrifuged for 1 h at 100,000 3 g. Then, 0.5-ml aliquots were
layered on linear 10–40% (in 10 mM Tris-HCl, pH 7.5) or 10–60%
(in 5:1 buffer without detergent) sucrose gradients and subjected to
centrifugation for 16 h at 23,000 rpm (10–40%) or for 18 h at 35,000
rpm (10–60%) in an SW40 rotor (Beckman Instruments, Munich).
Fractions of 0.4 ml (from 10–40% gradients) or 0.8 ml (from
10–60% gradients) were collected from top to bottom, and proteins
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were analyzed by SDSyPAGE directly or after immunoselection. In
parallel gradients, BSA (Sigma), catalase, thyroglobulin (Amer-
sham Pharmacia), or ribosomal subunits from X. laevis ovaries were
used as reference proteins or particles.
For gel filtration, cell extracts prepared by lysing cells from
three confluent 10-cm plates in a final volume of 0.6 ml of 5:1
buffer containing 0.1% Triton X-100 and 5 mM b-mercapto-
ethanol instead of DTT were centrifuged at 15,000 3 g for 10
min, followed by 100,000 3 g for 1 h. Then, 0.2 ml of the
supernatant was loaded on a Superose 12-h 10y30 column
(Amersham Pharmacia), and proteins were eluted with 5:1
buffer at a flow rate of 0.2 mlymin. Proteins from 0.4-ml
fractions were precipitated with 3 volumes of absolute methanol
and analyzed by SDSyPAGE.
Protein Fractions Containing Pol III. HeLa cells stably transfected
with flag epitope-tagged RPC53 (line BN51) were used. Pol III
was affinity-purified from S100 extracts by using BC buffer (20
mM Hepes, pH 7.9, 20% glycerol, 0.5 mM EDTA, 1 mM DTT,
and 0.5 mM PMSF) containing 300 mM KCl and 0.1% Nonidet
Fig. 1. Sucrose gradient sedimentation of plakophilin 2-containing particles extracted with 5:1 buffer (a) or physiological salt buffer (b) from human
keratinocyte cultures (HaCaT) or from HaCaT nuclei (c) in a linear 10–40% sucrose density gradient. Fractions were collected from top to bottom (1–30) and
analyzed by SDSyPAGE and immunoblotting for plakophilin 2, which is recovered in fractions corresponding to S values of ’11, 30–35, and 50–55 S (a), 40 and
55 S (b), and 55–60 S (c). L, loading sample. Size references: catalase, 11 S; X. laevis ribosomal subunits, 40 and 60 S.
Fig. 2. Plakophilin 2 interacts with RPC155. (a) Coimmunoselection of RPC155 with plakophilin 2. Extracts from cultured A-431 cells were subjected to immunos-
election with plakophilin 2 antiserum (lane 1; lane 2, control showing the proteins of the same antiserum bound to protein A-Sepharose), and the proteins selected
wereanalyzedbySDSyPAGEandstainedwithCoomassiebrilliantblue (thesizesof referenceproteinsare indicated).The155-kDapolypeptide (upperarrow)coselected
with plakophilin 2 (lower arrow) was excised from the gel and identified by matrix-assisted laser desorption ionization analysis as the largest subunit of RNA polymerase
III (RPC155). (b)Peptidesequencesdeterminedinthe155-kDabindingpartnerofplakophilin2bymatrix-assisted laserdesorptionionizationanalysis. Inaddition,myosin
heavy chain and major vault protein (42) were identified as apparently nonspecifically bound coadsorbed proteins (cf. ref. 7). (c) Blot-overlay assay of polypeptides of
a chromatographic fraction enriched in pol III, separated by SDSyPAGE, and visualized with Coomassie brilliant blue (lane 1) or transferred to nitrocellulose membranes
(lanes 2 and 3). After incubation with in vitro translated 35S-labeled plakophilin 2, the binding partners of plakophilin 2 within the pol III fraction were detected by
autoradiography(lane2).A155-kDaprotein,whichwas identifiedsubsequentlyas the largest subunitofpol IIIby immunoblotanalysisusingRPC155-specificantibodies
(lane 3), binds plakophilin 2 selectively. The position of reference proteins is indicated on the left.
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P-40 (20). Pol III holoenzyme was enriched from nuclear extracts
and immunopurified in BC buffer containing 100 mM KCl and
0.05% Nonidet P-40 (19).
Immunoisolation and Matrix-Assisted Laser Desorption Ionization
Analysis. Confluent A-431 cells of 200 Petri dishes (10-cm
diameter) were lysed (0.6 ml per dish) in ice-cold modified RIPA
buffer (20 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
DTT, 1 mM PMSF, and 13 Complete protease inhibitors) and
homogenized in a Dounce-type glass homogenizer (all proce-
dures were performed at 4°C). After centrifugation for 1 h at
100,000 3 g, the supernatant was incubated for 2 h with 20 mg
of protein A-Sepharose beads (Amersham Pharmacia) and
cleared by centrifugation. The lysate was incubated overnight
with the beads bound with 200 ml of plakophilin 2 antibodies, and
the selected protein complexes were washed four times in RIPA
buffer and analyzed by SDSyPAGE. Bands seen after Coomassie
blue staining were excised and digested in the gel for peptide
fingerprinting by matrix-assisted laser desorption ionization
mass spectrometry (22). For sequence comparisons, the pro-
grams Peptide Search (European Molecular Biology Labora-
tory), MS-Fit (University of California, San Francisco), and
ProFound (Rockefeller University, New York) were used.
Immunoselections. Immunoselected complexes from sucrose gradi-
ent fractions were obtained with material from five parallel gradi-
ents (10–60%). The fractions were pooled, adjusted by adding the
double volume of 23 RIPA buffer, and obtained after preclearing
with protein A-Sepharose for 2 h. Samples were incubated over-
night with protein A-Sepharose beads coated with plakophilin 2
antibodies. Before analysis by SDSyPAGE, the immunoselected
material was washed four times with RIPA buffer.
Extracts from lysed MCF-7 cells were prepared by immuno-
selection buffer (20 mM Hepes, pH 7.9, 10% glycerol, 2 mM MgCl2,
100 mM KCl, 0.1% Triton X-100, 1 mM DTT, 1 mM PMSF, and
13 Complete protease inhibitors). After centrifugation at 15,000 3
g for 20 min, the supernatants were preincubated with Sepharose
beads and subjected to immunoselection as described by using
rabbit antibodies against one of the pol III components. In all
washes, the buffer was the same as that used for lysis.
Blot Binding Assays. A pol III-enriched fraction was prepared
from HeLa S100 extracts (18–20), separated by SDSyPAGE, and
transferred to nitrocellulose membrane sheets. [35S]methionine-
labeled plakophilin 2 was obtained by coupled in vitro transcrip-
tion-translation of plakophilin 2 cDNA or a subclone encoding
the amino-terminal domain only (residues 1–367; ref. 6) using
the coupled transcription and translation reticulocyte lysate
system (Promega). Binding assays were as described (7).
Fig. 3. Gel filtration of plakophilin 2 and RPC155. Triton X-100-soluble extracts from human PLC cell cultures were chromatographed on a Superose 12 column,
and individual fractions were analyzed by immunoblotting with antibodies against plakophilin 2 and RPC155. The elution peaks of the size markers (kDa) Dextran
blue 2000 (2,000), thyroglobulin (669), catalase (232), and BSA (66) are indicated by arrows. Plakophilin 2 and RPC155 co-elute in a position corresponding to
’1,500 kDa (fractions 6–8). L, loading sample.
Fig. 4. Analysis of plakophilin 2: RPC155 complexes by ribonuclease treatment and immunoselection. (a) Sedimentation of plakophilin 2 and RPC155 in sucrose
density gradients (10–60%) from A-431 cell extracts without and with RNase A treatment. After centrifugation, proteins from individual fractions were
precipitated with absolute methanol, subjected to SDSyPAGE, and analyzed by immunoblotting with antibodies against plakophilin 2 and RPC155. Size
references: BSA, 4.5 S; catalase, 11 S; and thyroglobulin, 16.5 S. (b) For coimmunoselection of plakophilin 2 and RPC155 from sucrose density gradient fractions
(no RNase treatment), fractions 9 and 12 (a) were subjected to immunoselection by using either antibodies specific for plakophilin 2 or unrelated antibodies
(Contr.). Fractions were analyzed by immunoblotting with antibodies against plakophilin 2 and RPC155. RPC155 coimmunoselects with plakophilin from both
fractions tested, whereas no signal is found in the negative controls.








Immunofluorescence Microscopy. For immunofluorescence mi-
croscopy, cultured cells grown on coverslips were briefly rinsed
in phosphate-buffered saline prewarmed to 37°C. Cells were
fixed at 220°C in methanol (for 5 min) and acetone (for 30 sec)
and air-dried. For double-staining experiments, guinea pig an-
tibodies against plakophilin 2 and rabbit antisera specific for
RPC155 were applied for 30 min followed by three phosphate-
buffered saline washes for 3 min each. Secondary antibodies
coupled to Texas red or fluorescein isothiocyanate (Dianova,
Hamburg, Germany) were applied for 30 min. After washing
with phosphate-buffered saline, the specimens were rinsed in
water, briefly dipped in ethanol, air-dried, and mounted with
Fluoromount (Biozol, Eching, Germany). Confocal laser scan-
ning immunofluorescence images were acquired with a Zeiss
LSM 410 microscope (Zeiss; ref. 6–8).
Results
Plakophilin 2-Containing Complexes. To study the native state of
nuclear plakophilin 2, rapid particle extracts from cultured cells in
Triton X-100 and EDTA were subjected to sucrose density gradient
centrifugation, and the fractions obtained were analyzed by SDSy
PAGE and immunoblotting (Fig. 1a). Plakophilin 2 was recovered
in three peak fractions. The majority of the protein sedimented in
large complexes of 30–35 S (fractions 14–17) and 50–55 S (fractions
20–23), whereas a minor proportion appeared at ’11 S (fractions
6 and 7). Corresponding sedimentation profiles were obtained with
extracts from various human cell lines such as HaCaT, A-431, or
PLC, although the relative recovery in the different peak fractions
varied somewhat.
Because plakophilin 2 is rather susceptible to proteolytic
breakdown, most of the experiments were performed with
rapidly isolated complexes. Under more protective conditions
(physiological salt buffer) without EDTA, the two major peaks
appeared at about 40 and 55 S (Fig. 1b). By contrast, when
isolated nuclei were washed and subjected to particle extractions,
only a single 55–60 S peak was predominant (Fig. 1c).
Plakophilin 2 in Complexes with the Largest Subunit of Pol III. When
extracts from A-431 cells were subjected to immunoselection
with antibodies against plakophilin 2, a 155-kDa polypeptide was
specifically coselected (Fig. 2a, arrow in lane 1; see also ref. 7).
On analysis by mass spectrometry and peptide fingerprinting,
this polypeptide was identified as the largest subunit of pol III
(Fig. 2b, RPC155; cf. ref. 18–20).
In Vitro Binding of Plakophilin 2. The association between plako-
philin 2 and RPC155 was demonstrable also in vitro. When
fractions of nuclear proteins enriched in pol III were subjected
to SDSyPAGE (Fig. 2c, lane 1), blotted onto nitrocellulose
membranes, and reacted with radioactively labeled plakophilin
2, specific and intense binding to the band containing RPC155
was noted (Fig. 2c, lanes 2 and 3).
Biochemical Characterizations. To examine the distribution of
particles containing plakophilin 2 and RPC155, extracts from
various cell cultures were subjected to gel filtration on a Super-
ose 12 column, and the fractions obtained were analyzed by
immunoblotting (Fig. 3). The majority of plakophilin 2 eluted in
a rather broad peak (fractions 4–11) briefly after the void
volume. In agreement with the sedimentation analysis (Fig. 1),
smaller amounts coeluted with the reference protein catalase
(fraction 21). RPC155 copurified with plakophilin 2 in peak
fractions 6–9, corresponding to a mean molecular mass of
’1.5 3 106. In addition, some RPC155 eluted as a distinct
complex with a relative weight of about 700,000, which corre-
sponds to the weight of the native catalytically active 16-subunit
pol III complex (23).
To characterize particles containing plakophilin 2 and
RPC155 further, they were subjected to centrifugation on 10–
60% sucrose gradients. Both RPC155 and plakophilin 2 were
detected in fractions 9 and 12, corresponding to 30–35- and
50–55-S complexes, respectively (Fig. 4a, Left). Moreover, we
noted that treatment with RNase A had an effect on the
sedimentation behavior of the plakophilin 2-containing parti-
cles, which shifted to positions corresponding to smaller sizes
(Fig. 4a, Right). By contrast, DNase treatments did not alter the
sedimentation profiles (data not shown; ref. 7). These results may
suggest that plakophilin 2 and RPC155 are components of particles
that also contain some RNA of an as yet unknown nature.
To characterize the particles containing plakophilin 2 and
RPC155 further, plakophilin 2 was immunoselected from the
peak sucrose gradient fractions (Fig. 4b presents fractions 9 and
12, for example). Immunoblot analysis demonstrated that
Fig. 5. Plakophilin 2 is a component of the pol III holoenzyme complex. (a) For
immunoselection, proteins extracted from human MCF-7 carcinoma cells were
reacted with antibodies against the pol III subunits RPC39, RPC82, and RPC155 as
well as with antibodies specific for the transcription factors TFIIIB (90-kDa sub-
unit) and TFIIIC (63-kDa subunit), respectively. For control, preimmune serum was
used. The immunoselected fractions were analyzed by immunoblotting using
antibodies against RPC155 and plakophilin 2. The result shows the presence of
plakophilin 2 in particles specifically selected with antibodies to different pol III
components (RPC39, RPC82, RPC155, and TFIIIB) but not to TFIIIC (note that here
the specific enrichment of RPC155 is too low to show plakophilin 2). (b) Immu-
noblot detection of plakophilin 2 in the purified pol III holoenzyme. Lane 1, S100
extract from human embryonic kidney (HEK) cells; lane 2, nuclear extract from
HEK cells; lane 3, 5 ml of the FLAG-eluted pol III holoenzyme; lane 4, 5 ml of the
FLAG-eluted pol III core enzyme.
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RPC155 was associated physically with plakophilin 2 (Fig. 4b),
indicating that both proteins are part of the same complex.
We also scored the sucrose gradient fractions for other known
desmosomal components. Desmogleins, desmoplakin, and pla-
koglobin appeared in fractions showing no cosedimentation with
plakophilin 2 (data not shown; ref. 7). Plakophilins 1 and 3 were
recovered in similarly sized particle fractions, which however did
not contain pol III.
The Pol III Holoenzyme Complex. The size of the complex contain-
ing plakophilin 2 and RPC155 corresponds to that of the pol III
holoenzyme, which consists of pol III and all basal factors
essential for transcription (23). To examine whether plakophilin
2 was also associated with other components of the pol III
holoenzyme, extracts prepared from MCF-7 cells were immu-
noselected with antibodies against other pol III components and
analyzed for the presence of RPC155 and plakophilin 2 by
immunoblotting (Fig. 5a). RPC155 and plakophilin 2 both
appeared together with the 39-kDa subunit (RPC39) in combi-
nation with the 82-kDa pol III subunit (RPC82) and were
associated also with transcription initiation factor TFIIIB. No
binding was found to the primary DNA-binding factor TFIIIC
(Fig. 5a).
Affinity-purification studies using nuclear extracts from HeLa
cells stably transfected with a FLAG-tagged form of the RPC53
subunit resulted in the recovery of a functional pol III-
containing complex, the holoenzyme, capable of transcription
initiation and consisting of a multitude of distinct factors (cf. refs.
18–21). Among them one was identified as a ’100-kDa polypep-
tide corresponding in size to plakophilin 2 (6–8). Indeed,
immunoblot analysis (Fig. 5b) revealed a strong plakophilin 2
signal in fractions containing the affinity-purified pol III ho-
loenzyme (lane 3). By contrast, no plakophilin 2 reaction was
observed in fractions containing exclusively the 16-subunit pol
III, the so-called core enzyme (lane 4), indicating that plako-
philin 2 was associated with the pol III holoenzyme but not the
pol III core enzyme complex.
Immunolocalization Microscopy of the Nuclear Particles Containing
Plakophilin 2 and Pol III. The nuclear particles containing plako-
philin 2 and RPC155 were visualized directly by double-label
immunofluorescence microscopy in several cell culture lines. For
example, the reaction on PLC cells is shown in Fig. 6. Plakophilin
2 and RPC155 displayed a granular nucleoplasmic immunostain-
ing and colocalized in distinct nuclear structures (Fig. 6c, yellow
dots). However, in addition to these particles containing both
proteins, each of them also occurred in separate granules as
indicated by the non-yellow dots. This finding suggests that only
a portion of nuclear plakophilin 2 is associated with complexes
containing RPC155 and that both proteins also exist in other
forms specific for either protein. Moreover, the plakophilin
2-positive dots were different from those immunostained for
plakophilins 1 and 3 (data not shown).
Discussion
We have begun to characterize the nucleoplasmic forms of
plakophilin 2, a protein also known as a major component of
desmosomes. In particle fractionation and immunoselection
experiments as well as in in vitro binding assays, plakophilin 2
has been detected in specific complexes with the largest
subunit of RNA polymerase III (RPC155), the pol III subunit
of 39 kDa and transcription factor TFIIIB and also in distinct
nucleoplasmic granules. Both plakophilin 2 and RPC155 are
also part of two large multisubunit complexes that appear,
depending on the specific extraction conditions, between
30–35 and 50–60 S. Moreover, we have identified plakophilin
2 as one of the polypeptides enriched in affinity-purified
preparations of the pol III holoenzyme. This interaction
between plakophilin 2 and pol III components may provide a
clue to one of the hitherto unknown nuclear functions of a
junctional plaque protein.
Of the three nuclear RNA polymerases (I–III), pol III tran-
scribes genes encoding ribosomal 5S RNA, the tRNAs, signal
recognition particle RNA, U6 small nuclear RNA, and several
small viral RNAs (for review see ref. 23). The inclusion of
plakophilin 2 in nucleoplasmic assembly forms of the pol III
transcription machinery would be compatible with the wide-
spread and constitutive occurrence of plakophilin 2 in nuclei
(6–8), a situation that is fundamentally different from the
transient signal-induced nuclear translocation reported for other
proteins of the arm-repeat family such as b-catenin and plako-
globin (24–31) and suggests that it serves some general nuclear
function.
Fig. 6. Colocalization of plakophilin 2 and RPC155 in nuclear particles. Cultured PLC cells were double-immunolabeled with antibodies against plakophilin 2
(a, red) and RPC155 (b, green) and observed by confocal laser scanning microscopy. Both proteins exhibit a finely punctate nucleoplasmic immunostaining,
sparing the nucleoli. They colocalize in many nuclear particles as indicated (yellow) in the merged image (c, arrows). These structures are different from various
other nucleoplasmic granules examined in parallel (for antibodies used see refs. 43 and 44). In addition, one sees some dots mutually exclusive for pol III (green)
or plakophilin 2 (red). (Scale bar, 20 mm.)








The human pol III of ’700 kDa representing the core complex
contains 16 subunits that remain tightly associated with each
other even under partially denaturing conditions (e.g., see refs.
18–21). Its largest subunit (RPC155), shown here in complexes
with plakophilin 2, has been highly conserved throughout evo-
lution (18, 23, 32), as have amino acid sequence motifs in other
pol III subunits (23, 33, 34). Accurate transcription by pol III
requires the initiation factors TFIIIB and TFIIIC (35) and an
ordered sequence of steps for their assembly into preinitiation
complexes. On the other hand, affinity purification of pol III
from nuclear extracts has revealed a preassembled nucleoplas-
mic particle (holoenzyme) containing the 16-subunit pol III and
all basal factors essential for transcription (19, 23, 35, 36). Our
results indicate that plakophilin 2 may be added to the list of
components that can be present in this pol III holoenzyme
complex.
The pol III complexes with plakophilin 2 seem to be located
free in interchromatin spaces of the nucleoplasm, although their
specific distribution in relation to transcriptionally engaged
chromatin sites (37) remains to be established. We think that the
particles described are not engaged in transcription but represent
preinitiation assembly or storage forms, from which complexes
active in transcription or RNA processing might be recruited (19,
23, 27, 38). A special kind of nucleoplasmic assembly granules
has been described in amphibian oocytes and shown to harbor
not only pol III but also other kinds of polymerases (transcrip-
tosomes) and to aggregate to very large sizes up to 20 mm in
diameter (Cajal bodies; refs. 39–41). Clearly, future studies will
have to reveal the functional roles of both the Cajal bodies and
the much smaller plakophilin 2-containing granules of somatic
nuclei.
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